Looking at the micro data, we have an uptrend where we're following along the rising bottom. Looking a bit further out, we can see we're in a bullish wedge. General trends say that this will come up, and the company will have only good news about their trials progressing which will drive the price higher. Very near to $2 by the end of February, and we could...
After the good news this morning, the CNTB just got a big dip from one of the whales with weak resistance buyback force resulting in a sum of 3mil shares exchanged between buy and sale leading to a current ~$1.4. However, I noticed a similar pattern around October time where a bullish push for $1.2 and a big dip after that down to $0.79. This dip is almost 36% dip...
Here is a quick analysis of the CNTB chart and how it runs for whoever is interested in startup stocks. The advisory board of CNTB seems to be solid with Eli Lilly holding roughly 3.5% shares. This is not financial advice, please invest with care!
Without looking at the news, the CNTB should have gone down to get more air and stay around the $1.6 zone to be attractive. However, the new news regarding Simcere obtained the exclusive deal with CNTB regarding phase 3 drug rademikibart providing CNTB immediate big funding ($21M-$121M). This may signal a very bullish run if the market receives this news as...